Guide to buying Bausch + Lomb stock in Canada

Bausch + Lomb Corporation, an eye health company responsible for producing popular contact lens brands like Biotrue and Soflens, is planning to go public. Here's what we know—and how to buy Bausch + Lomb Corporation stock in Canada when it launches.

Bausch + Lomb (BLCO) stock summary

Company stock name	Bausch + Lomb Corp
Stock ticker symbol	BLCO
Exchange	Toronto Stock Exchange
Open	C$23.65
High	C$23.79
Low	C$23.55
Close	C$23.72
Adjusted closing	C$23.72
Volume The number of stocks traded during the day	1,000
52-week stock price range	C$14.56 – C$29.30
Where to buy Bausch + Lomb stock	Buy on CIBC Investor's Edge

The values in this table are accurate as of the market close on December 2, 2025, and all amounts are in CAD.

Can I buy Bausch + Lomb stock in Canada?

Yes, you can buy Bausch + Lomb stock in Canada. You simply need to open a brokerage account with an online trading platform that supports stocks on the Toronto Stock Exchange (TSX) exchange. Platforms like Interactive Brokers will allow you to directly buy Bausch + Lomb stock from within Canada.

Dive deeper: Detailed guide on how to buy stocks in Canada

Our top picks for where to buy Bausch + Lomb stock

Bausch + Lomb stock chart (Toronto Stock Exchange (TSX): BLCO)

This chart tracks Bausch + Lomb stock price performance over time.

Bausch + Lomb stock price

Bausch + Lomb's stock price at the last available market close was C$23.72 (as of December 2, 2025). Keep in mind that Bausch + Lomb's stock price can be impacted on a daily, or even hourly, basis by factors like company performance, the broader economy and investor sentiments.

Is Bausch + Lomb stock a buy or sell right now?

The technical analysis gauge above shows real-time buy or sell ratings and analysis for Bausch + Lomb stock based on your selected timeframe. It uses three widely followed indicators—moving averages, oscillators and pivots—but this does not represent investment advice or a guarantee of success. Finder may not concur with these signals and accepts no responsibility for the performance of your stocks.

Can I buy Bausch + Lomb stock on the TSX?

No, you cannot buy Bausch + Lomb stock on the TSX because Bausch + Lomb stock is not listed on the TSX. Instead, Bausch + Lomb stock is listed on the Toronto Stock Exchange under the symbol "BLCO."

That said, if you're wondering how to invest in Bausch + Lomb stock in Canada, you still have the option to do so by opening a trading account with a Canadian brokerage that gives you access to Toronto Stock Exchange, like Interactive Brokers.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Bausch + Lomb stock dividends

Bausch + Lomb is not expected to pay a dividend over the next 12 months. We'll continue to monitor Bausch + Lomb's stock information and update this guide if that changes.

Bausch + Lomb stock performance metrics

Here are some common key metrics for Bausch + Lomb stock that analysts often use to help gauge a stock's value—P/E ratio, PEG ratio and EBITDA.

• Bausch + Lomb's P/E ratio

  Bausch + Lomb's current share price divided by its per-share earnings (EPS) over the past 12 months gives a trailing price/earnings (P/E) ratio of roughly 0x. In other words, Bausch + Lomb shares trade at around 0 times recent earnings.

• Bausch + Lomb's PEG ratio

  Bausch + Lomb's price/earnings-to-growth (PEG) ratio is calculated by dividing its P/E ratio by its earnings growth, which comes out to about 0.7019. A lower ratio can suggest a stock offers better value, while a higher ratio may suggest worse value.

  The PEG ratio provides a broader view than the P/E ratio alone, as it factors in Bausch + Lomb's expected earnings growth. By accounting for growth, investors can use the PEG ratio to compare the valuations of multiple high-growth companies.

• Bausch + Lomb's EBITDA

  Bausch + Lomb's EBITDA (earnings before interest, taxes, depreciation and amortization) is C$544 million. EBITDA is a measure of a company's overall financial performance and is often used as a proxy for a company's profitability.

How volatile is Bausch + Lomb stock?

Over the last 12 months, Bausch + Lomb's stocks price has ranged from C$14.56 to as high as C$29.30. Bausch + Lomb's beta measurement of stock volatility is 0.63. For comparison, the market (Toronto Stock Exchange) average beta is 1. This would suggest that Bausch + Lomb's stocks are less volatile than average (on this exchange).

Some analysists use "beta" to gauge a stock's volatility. Beta is a popular way to measure a stocks volatility in relation to the market. Here is a breakdown of Bausch + Lomb's beta stock volatility rating.

Bausch + Lomb company and revenue performance

Market Capitalization The total market value of Bausch + Lomb's outstanding shares	C$8 billion
Gross profit (TTM)	C$3 billion
Operating margin (TTM)	6.25%
Profit margin	-6.13%
Revenue (TTM)	C$5 billion
Return on assets (TTM)	0.53%
Return on equity (TTM)	-4.50%
Earnings per share (TTM)	-C$1.20
50-day moving stock price average The average share price over the last 50 days	C$21.39
200-day moving stock price average The average share price over the last 200 days	C$19.56

All dollar amounts in this table are in CAD. TTM refers to the "trailing 12 months." All values are accurate as of the market close on December 2, 2025.

Bausch + Lomb company profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.

The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provides optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery.

The company sells its products and services through direct sales forces and independent distributors.

• Common company-related questions about Bausch + Lomb

  What percentage of Bausch + Lomb is owned by insiders or institutions?
  Currently 89.014% of Bausch + Lomb stocks are held by insiders and 11.289% by institutions.

  How many people work for Bausch + Lomb?
  Latest data suggests 13,500 work at Bausch + Lomb.

  When does the fiscal year end for Bausch + Lomb?
  Bausch + Lomb's fiscal year ends in December.

  Where is Bausch + Lomb based?
  Bausch + Lomb's address is: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4

  What is Bausch + Lomb's ISIN number?
  Bausch + Lomb's international securities identification number is: CA0717051076

  What is Bausch + Lomb's CUSIP number?
  Bausch + Lomb's Committee on Uniform Securities Identification Procedures number is: 071705107

Compare trading platforms to buy Bausch + Lomb Corporation stock

Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.

Related: Compare the best stock trading platforms in Canada

Do I have to pay tax on gains from Bausch + Lomb stock sales in Canada?

Yes, you'll need to pay taxes in Canada on investment income, which includes any profit from selling Bausch + Lomb stock. The CRA taxes investment income from stocks in Canada based on three main factors:

1. Investment income. Investment income includes money earned from interest, dividends or capital gains, which may affect how much you have to pay in taxes on stock sales in Canada.
2. Investor type. Your investment income will be taxed differently depending on whether you're a regular investor or a day trader (which means you buy and trade stocks on a daily basis as your primary form of income).
3. Tax bracket. The higher your tax bracket, the more you'll pay on income from stock sales. Your tax bracket depends on your gross income (minus deductions).

You can learn more about the tax implications of selling stocks in Canada here.

Frequently asked questions about Bausch + Lomb stock

• Can I buy Bausch + Lomb stock directly as a Canadian investor?

  Yes, Canadian investors can buy Bausch + Lomb stock directly through various online brokerage platforms available in Canada. You can compare trading platform options and fees for buying Bausch + Lomb stock in our table here.

• How much is Bausch + Lomb stock worth?

  As of the last market close (on December 2, 2025), Bausch + Lomb stock is worth C$23.72 per share.

• Can Canadians buy American stocks?

  Yes, Canadians can buy American stocks through Canadian trading platforms that give access to American stock exchanges such as the NYSE and Nasdaq. The good news is that most Canadian brokerage platforms, like Questrade, Interactive Brokers, Moomoo and Wealthsimple, give access to US exchanges. Read our full guide on how to buy US stocks in Canada to learn more.

• Can I buy fractional shares of Bausch + Lomb stock?

  Yes, it may be possible to buy fractional shares of Bausch + Lomb stock depending on the trading platform you're signed up with. Fractional shares can allow you to invest in Bausch + Lomb stock even when you can't afford its full share price. You can read our full guide to how fractional shares work to learn more.

  The table below shows trading apps in Canada that offer fractional shares:

  3 of 3 results

  Finder Score	Available Asset Types	Account Types	Stock Trading Fee	Monthly Account Fee
  Promoted Finder Score 8.8 Great Interactive Brokers	Finder Score 8.8 Great	Stocks, Bonds, Options, Index Funds, ETFs, Forex, Currencies, Futures	RRSP, TFSA, Personal, Joint	min $1.00, max 0.5%	$0	Go to site More info Compare product selection Compare	loading
  Finder Score 7.4 Great Moomoo Financial Canada	Finder Score 7.4 Great	Stocks, Options, ETFs	RRSP, TFSA, Personal, FHSA	$1.49/stock	$0	Get up to $4,600 in trading perks. T&Cs apply.	Go to site More info Compare product selection Compare	loading
  Finder Score 9.1 Excellent Questrade	Finder Score 9.1 Excellent	Stocks, Bonds, Options, Mutual Funds, Index Funds, ETFs, Forex, GICs, Precious Metals, IPOs	RRSP, RESP, RRIF, TFSA, Personal, Joint, FHSA	$0	$0	Get free contracts, no commissions and a 30 day free trial of Questrade Plus. Use offer code FREEOPTIONS. T&Cs apply.	Go to site More info Compare product selection Compare	loading

  loading

  Load More

  Showing 3 of 3 results

  Finder Score for stock trading platforms

  To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.

  Read the full methodology

Related: New to stock trading? Compare brokers and get tips for investing.

Important information: Powered by Finder.com. This information is general in nature and is no substitute for professional advice. It does not take into account your personal situation. This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for most investors. You do not own or have any interest in the underlying asset. Capital is at risk, including the risk of losing more than the amount originally put in, market volatility and liquidity risks. Past performance is no guarantee of future results. Tax on profits may apply. Consider the Product Disclosure Statement and Target Market Determination for the product on the provider's website. Consider your own circumstances, including whether you can afford to take the high risk of losing your money and possess the relevant experience and knowledge. We recommend that you obtain independent advice from a suitably licensed financial advisor before making any trades.